Beijing Kairui Innovation Pharmaceutical Technology

Beijing Kairui Innovation Pharmaceutical Technology is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule therapeutics for oncology and metabolic diseases. The company leverages its internal R&D capabilities to target well-validated pathways such as EGFR and KRAS, with a particular emphasis on overcoming drug resistance in lung and gastrointestinal cancers. Its lead programs include next-generation kinase inhibitors designed to provide superior efficacy and safety profiles compared to existing standards of care. Kairui Innovation is headquartered in Beijing and maintains a robust pipeline of candidates ranging from discovery to mid-stage clinical trials.